Earnings are out
Scribe Therapeutics (SCTX)
Develops CasX-based genetic medicines for lipid-linked cardiometabolic disease.
$30.80
Pre-market−0.01 (−0.03%)
At close$30.81(+6.24%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Strategic holders1 holder · as of Jul 23, 2026 | 6.52% | 1.05M shares | |
| Otherremainder | 93.48% | 15.13M shares |
16.18M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.